New Delhi: Indian pharmaceutical companies may struggle to transfer tariff costs to US consumers if imposed, warns Amit Varma of Quadria Capital. He stresses the vital role these firms play in the US market and the potential disruptions tariffs could cause to supply chains.
Indian pharmaceutical companies may face significant challenges in passing on tariff costs to US consumers if the Donald Trump administration chooses to impose such tariffs, according to Amit Varma, managing partner at Quadria Capital. Speaking to NDTV Profit, Varma highlighted the critical role Indian firms play in supplying "life-threatening drugs" to the US market, emphasising the potential repercussions of tariffs on supply chains.
Varma expressed concern that any disruption in supply chains could instigate a considerable public outcry, urging efforts to find ways to circumvent such challenges. He warned that if tariffs reach double-digit levels, there would likely be a negative impact on the balance sheets of Indian pharmaceutical companies.
He further commented on the difficulty of completely relocating manufacturing and supply chains to the US, stating that "it is hard to pull off a complete shift". Varma pointed out that such a transition would take a long time due to the complex nature of these operations and the difficulty of replicating India’s established cost and price efficiencies.
Moreover, he discussed the dynamics within the contract development and manufacturing organisation (CDMO) sector, noting that contracts in this space are typically long-term commitments. Varma suggested that, in light of India's inherent cost efficiency, it is unlikely that US clients would abandon these partnerships, even if there are slight reductions in operating margins. Thus, while the potential imposition of tariffs could pose challenges, the established relationships and efficiencies may offer some resilience for Indian pharmaceutical firms.
Source: Noah Wire Services
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
6
Notes:
The narrative references the 'Donald Trump administration', which may indicate outdated information since Trump is no longer in office. However, the issue of tariffs remains relevant.
Quotes check
Score:
8
Notes:
Direct quotes from Amit Varma are included, but no specific online sources were found to verify these quotes as original or first-time usage.
Source reliability
Score:
9
Notes:
The narrative originates from NDTV Profit, a reputable news outlet in India, which generally provides reliable information.
Plausibility check
Score:
8
Notes:
The claims about the challenges faced by Indian pharmaceutical companies due to tariffs are plausible, given the complex nature of supply chains and manufacturing.
Overall assessment
Verdict (FAIL, OPEN, PASS): OPEN
Confidence (LOW, MEDIUM, HIGH): MEDIUM
Summary:
While the narrative is generally plausible and originates from a reliable source, the reference to the Trump administration suggests potential outdatedness. The quotes appear original but lack verification. Overall, the information seems credible but requires further context for full validation.
